JP2003500051A - 相互作用活性化タンパク質 - Google Patents

相互作用活性化タンパク質

Info

Publication number
JP2003500051A
JP2003500051A JP2000620079A JP2000620079A JP2003500051A JP 2003500051 A JP2003500051 A JP 2003500051A JP 2000620079 A JP2000620079 A JP 2000620079A JP 2000620079 A JP2000620079 A JP 2000620079A JP 2003500051 A JP2003500051 A JP 2003500051A
Authority
JP
Japan
Prior art keywords
fragment
protein
oligopeptide
lactamase
terminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000620079A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003500051A5 (https=
Inventor
エフ． バリント，ロバート
ハー，ジェン−ホーン
Original Assignee
パノラマ リサーチ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by パノラマ リサーチ，インコーポレイティド filed Critical パノラマ リサーチ，インコーポレイティド
Publication of JP2003500051A publication Critical patent/JP2003500051A/ja
Publication of JP2003500051A5 publication Critical patent/JP2003500051A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/986—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides (3.5.2), e.g. beta-lactamase (penicillinase, 3.5.2.6), creatinine amidohydrolase (creatininase, EC 3.5.2.10), N-methylhydantoinase (3.5.2.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2000620079A 1999-05-25 2000-03-16 相互作用活性化タンパク質 Pending JP2003500051A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13592699P 1999-05-25 1999-05-25
US60/135,926 1999-05-25
US17596800P 2000-01-13 2000-01-13
US60/175,968 2000-01-13
PCT/US2000/007108 WO2000071702A1 (en) 1999-05-25 2000-03-16 Interaction-activated proteins

Publications (2)

Publication Number Publication Date
JP2003500051A true JP2003500051A (ja) 2003-01-07
JP2003500051A5 JP2003500051A5 (https=) 2005-07-28

Family

ID=26833822

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000620079A Pending JP2003500051A (ja) 1999-05-25 2000-03-16 相互作用活性化タンパク質

Country Status (5)

Country Link
EP (1) EP1183347A1 (https=)
JP (1) JP2003500051A (https=)
AU (1) AU6045900A (https=)
CA (1) CA2374476A1 (https=)
WO (1) WO2000071702A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517914A (ja) * 2004-10-22 2008-05-29 ジェネンコー・インターナショナル・インク ヒトの抗体の分離方法
JP2017518083A (ja) * 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6828099B2 (en) * 1998-02-02 2004-12-07 Odyssey Thera Inc. Protein fragment complementation assay (PCA) for the detection of protein-protein, protein-small molecule and protein nucleic acid interactions based on the E. coli TEM-1 β-Lactamase
US8148110B2 (en) 1999-03-15 2012-04-03 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by β-lactamase reporter fragment complementation
US7252952B2 (en) * 2000-03-06 2007-08-07 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein—protein interaction
US7566765B2 (en) 2000-03-06 2009-07-28 Rigel Pharmaceuticals, Inc. Heterocyclic compounds containing a nine-membered carbon-nitrogen ring
US7378248B2 (en) 2000-03-06 2008-05-27 Rigel Pharmaceuticals, Inc. In vivo production of cyclic peptides for inhibiting protein-protein interaction
AU2002227112A1 (en) * 2000-10-30 2002-05-15 Kalobios, Inc. Affinity maturation by competitive selection
KR100440746B1 (ko) * 2001-02-07 2004-07-23 (주)비엠에스 항생물질 내성균 선별을 위한 유전형 분석키트
EP1392870B1 (en) * 2001-05-09 2008-02-27 Discoverx, Inc. Screening for enzyme inhibitors
WO2003040670A2 (en) * 2001-11-07 2003-05-15 Sensor Technologies Llc Method of identifying energy transfer sensors for analytes
US20030157579A1 (en) * 2002-02-14 2003-08-21 Kalobios, Inc. Molecular sensors activated by disinhibition
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US7335478B2 (en) 2002-04-18 2008-02-26 Kalobios Pharmaceuticals, Inc. Reactivation-based molecular interaction sensors
WO2004072266A2 (en) * 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
WO2007054658A1 (en) * 2005-11-14 2007-05-18 King's College London Control of immune responses
US8426138B2 (en) 2006-12-26 2013-04-23 The Board Of Trustees Of The Leland Stanford Junior University Detection of sub-cellular compartment localization of a molecule using a reduced affinity enzyme complementation reporter system
US8101373B2 (en) 2007-10-12 2012-01-24 Discoverx Corporation β-galactosidase donor fragments
WO2013119579A1 (en) 2012-02-06 2013-08-15 Discoveryx Corporation Detection of intracellular binding events by measuring protein abundance
ES2778033T3 (es) 2012-11-16 2020-08-07 Poseida Therapeutics Inc Enzimas específicas de sitio y métodos de uso
EP2975126A1 (en) 2014-07-15 2016-01-20 Institut Pasteur In vivo detection of proteins interaction based on adenylate cyclase hybrid system
EP3929286A1 (en) 2015-06-17 2021-12-29 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585245A (en) * 1994-04-22 1996-12-17 California Institute Of Technology Ubiquitin-based split protein sensor
US5741657A (en) * 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
CA2196496A1 (en) * 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342345B1 (en) * 1997-04-02 2002-01-29 The Board Of Trustees Of The Leland Stanford Junior University Detection of molecular interactions by reporter subunit complementation
US6333154B1 (en) * 1997-12-04 2001-12-25 Institut Pasteur Bacterial multi-hybrid system and applications thereof
EP1027608B1 (en) * 1998-07-30 2010-01-20 Odyssey Thera, Inc. Protein fragment complementation assays

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008517914A (ja) * 2004-10-22 2008-05-29 ジェネンコー・インターナショナル・インク ヒトの抗体の分離方法
JP2017518083A (ja) * 2014-06-17 2017-07-06 ポセイダ セラピューティクス， インコーポレイテッド ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物

Also Published As

Publication number Publication date
EP1183347A1 (en) 2002-03-06
WO2000071702A1 (en) 2000-11-30
AU6045900A (en) 2000-12-12
CA2374476A1 (en) 2000-11-30

Similar Documents

Publication Publication Date Title
JP2003500051A (ja) 相互作用活性化タンパク質
JP7252278B2 (ja) 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
US20260085106A1 (en) Signalling System
US20210284721A1 (en) Modified antibody compositions, methods of making and using thereof
US6479280B1 (en) Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
US7544477B2 (en) Circularly permutated, interaction-activated proteins
AU2013331763B2 (en) Bispecific HER2 ligands for cancer therapy
Griffin et al. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting
JP2022527129A (ja) クローディン１８．２を標的とする抗体又はキメラ抗原受容体
US20030186385A1 (en) Method of identifying polypeptide monobodies which bind to target proteins and use thereof
KR101740030B1 (ko) ScFv 항체 라이브러리, 이의 제조방법 및 이를 이용한 ScFv 항체 스크리닝 방법
JP2019534038A (ja) Ｂｃｍａ特異的フィブロネクチンｉｉｉ型ドメインを有するキメラ抗原受容体、及びその使用
US12168684B2 (en) Antibody mimetic capable of being activated reversibly and uses thereof
CN116655794A (zh) 一种靶向t细胞淋巴瘤细胞的免疫细胞及其制备方法和应用
JP2004521616A (ja) 競合的選択による親和性成熟
CN114585730A (zh) 工程化调节性t细胞
US20040038317A1 (en) Breakpoint fusion fragment complementation system
JP2021518428A (ja) プログラム可能な免疫細胞受容体複合体システム
US20070042399A1 (en) Biological materials and uses thereof
Heitrich et al. Development of novel high-affinity nanobodies against EGFR for cancer therapy
CN120271685B (zh) 一种BiFC荧光互补对及其应用
CN119552270A (zh) 一种msln特异性嵌合抗原受体、car-t细胞及其应用
KR20250058686A (ko) Ct83 항원에 결합하는 car-t 세포 및 이의 용도
KR20260057295A (ko) Ct83 항원에 대한 인간 단클론 항체 및 이의 용도
CN121540887A (zh) Vars1基因的应用、vars1抑制剂和用途